Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)

By Keith Speights - May 18, 2018 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They're both rebounding nicely. But which is the smarter pick for long-term investors?

If you're looking for stocks that have made tremendous comebacks in 2018, Opko Health (OPK 3.95%) and Myriad Genetics (MYGN 2.53%) definitely fit the bill. Opko stock was down nearly 20% this year before roaring back. Myriad Genetics saw its share price plunge close to 40% earlier in 2018, but a strong rebound has the stock price close to where it began the year. 

Which of these two comeback stories is the better choice for investors now? Here's how Opko Health and Myriad Genetics stack up.

Red ribbon forming question mark on top of pile of $5, $10, $20, and $100 bills

Image source: Getty Images.

The case for Opko Health

Opko Health's Q1 results are a great place to start in determining why investors might want to consider the stock. After a painfully slow launch, secondary hyperparathyroidism (SHPT) drug Rayaldee began to enjoy some decent momentum. Total prescriptions for Rayaldee soared 730% year over year and jumped 38% higher than 2017 Q4.

Some analysts think that Rayaldee could reach peak annual sales in the ballpark of $700 million. There's a long way to go to hit that mark, but for the first time in quite a while, there's reason for some optimism about the drug.

The biggest source of revenue for Opko, though, is BioReference Labs (BRL). BRL is the third-largest clinical laboratory in the U.S. It focuses on genetic testing. In addition, BRL's sales team markets Opko's 4Kscore prostate cancer test. The business hasn't performed all that well in recent quarters. However, Opko put a new management team in place and thinks that BRL's revenue will improve in 2018.

Opko could have several new products on the way. The company hopes to get a green light soon from the FDA for marketing the Claros point-of-care prostate cancer test. A phase 3 clinical study is in progress evaluating human growth hormone product hGH-CTP in treating growth hormone-deficient children. The company also has several phase 2 pipeline candidates, including an experimental drug targeting treatment of benign prostatic hyperplasia, as well as type 2 diabetes and obesity drug OPK88003. 

One other reason many investors like Opko is the company's CEO, Phillip Frost. Frost is a billionaire with a long track record of success in the pharmaceutical industry. He has remained enthusiastic about Opko's prospects despite challenges through the years and has invested heavily in the company. 

The case for Myriad Genetics

Looking at Myriad Genetics' latest quarterly results also highlights the key arguments for the stock. Myriad topped expectations in fiscal Q3 thanks to surprisingly strong volume for its hereditary cancer testing. But the molecular diagnostics company has expanded into additional higher-growth areas, especially personalized medicine.

Myriad's most promising personalized medicine product is GeneSight, a genetic test that helps determine which antidepressant is best-suited for a particular patient. Myriad thinks that the global market size for this diagnostic test could be close to $10 billion. The company recently reported results from a large study that showed that patients with major depressive disorder (MDD) were 50% more likely to achieve remission and 30% more likely to respond to treatment when GeneSight was used to determine the appropriate medication.

The company also won FDA approval earlier this year for BRACAnalysis CDx as a companion diagnostic for Lynparza in breast cancer patients. AstraZeneca and Merck co-market Lynparza for treatment of breast cancer and ovarian cancer. 

BRACAnalysis CDx could be a significant source of growth for Myriad. Lynparza could eventually win approval for treating prostate cancer, pancreatic cancer, and other indications. If AstraZeneca and Merck pick up more approved indications for the drug, Myriad stands to benefit.

Don't write off Myriad's hereditary cancer business, either. The company launched a new product last year that could help gain market share. RiskScore helps predict the risk that a woman will develop breast cancer. The test uses clinical risk factors and genetic markers.  

Better buy

Both Opko Health and Myriad Genetics are enjoying nice rebounds and could have room to grow. I think, though, that Myriad is the better pick. In my view, the decision comes down to financial health. Opko continues to lose money, while Myriad is profitable. 

But while I think Myriad is the better choice, I don't see either of these stocks as great ones to buy right now. Myriad's shares currently trade at 26 times expected earnings. That steep valuation might be warranted if the company delivers on its potential. My preference, however, is to stay on the sidelines until there's more evidence that Myriad will be able to do so.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$18.63 (2.53%) $0.46
OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$2.63 (3.95%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.